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Background: Measuring satisfaction with treatment has proved useful to ascertain the treatment features that are
most important to the patients, and to explain increased treatment compliance. However, there are few studies
that relate satisfaction to other clinical or self-perceived health status indicators. Recent studies have shown the
close relationship between satisfaction with treatment, treatment compliance, and effectiveness. This study
attempts to design and validate a scale to evaluate satisfaction with antidepressant drug therapy, assess treatment
compliance (self-reported, validated questionnaire, drug accountability and electronic monitorization system), assess
efficacy in reducing depressive symptoms and safety in patients who initiate antidepressant drug therapy, as well as
to establish predictors of satisfaction, compliance and effectiveness with these drugs.
Methods/design: This is an observational longitudinal study with a cohort of adults initiating treatment with
antidepressant drugs. A multi-centre study will be performed in which 20 Primary Care practices from Castilla-La
Mancha are expected to participate. An initial interview and follow-up visits at 15 days, 1, 3, 6, 9 and 12 months will
be conducted with all study participants. 706 subjects will be studied (95% confidence interval, precision ± 3%,
expected rate of non-compliance 50%, expected non-responders and lost to follow up rate 15%). The following
measurements will be performed: development and validation of a scale of satisfaction with antidepressant therapy,
participant and antidepressant characteristics, treatment compliance evaluation (Haynes-Sackett Test, Morisky-Green
Test, drug accountability and Medication Event Monitoring System), depression symptom reduction (Hamilton
Depression Rating Scale and Montgomery-Asberg Depression Rating Scale), observation of adverse effects, and
beliefs about treatment (The Beliefs about Medicines Questionnaire).
Discussion: Antidepressant drugs are an extraordinarily important therapeutic group in the pharmacy composition;
economic repercussions and social impact associated to their use is clear. Despite their well-established efficacy in
clinical trials, treatment non-compliance is a major obstacle to their effectiveness in clinical practice. The proposed
study brings about useful conclusions to improve the results of these drugs. Additionally, devising a scale
specifically designed to evaluate satisfaction with antidepressant treatment could be of interest in healthcare
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Use of antidepressant drugs
Since their introduction, the prescription of novel anti-
depressant drugs (ADs) has increased dramatically [1].
The change in the psychiatric care model, now incor-
porated into the rest of specialties, within primary care
(PC) and closer to the patients, has been associated with
an increase in the diagnoses of depression [2] as well as
the indication for antidepressants –which are used to
treat depression and other disorders in 36% and 64% of
cases, respectively [3].
Treatment with ADs is initiated in the PC setting in
76.36% of cases. A study performed to ascertain the situ-
ation of depression-related healthcare in Spain [4] showed
that most PC physicians (95%) and psychiatrists (99%) pre-
scribe drug treatments to all their depressed patients. Both,
PC physicians and psychiatrists, mostly prescribe selective
serotonin reuptake inhibitors (SSRIs) as first line drugs
(93% of both samples). While SSRIs are considered to be
the most effective antidepressant group by PC physicians,
psychiatrists rather consider tricyclic antidepressants to be
the most effective.
As a consequence of the dramatic increase in their pre-
scription, antidepressants have become the third largest
pharmaceutical class sold in the year 2009 –only surpassed
by anti-ulcer drugs and hypolipemiants– resulting in not-
ably increased healthcare expenditures [5]. The actual clin-
ical impact of this increase is presently under discussion, as
is the possible abuse of these drugs in doubtful indications
or for indefinite periods of time, again with respect to the
impact on pharmaceutical expenditures. On the other hand,
a study where drug consumption and treatment duration
were analyzed [6] showed that a high percentage of in-
dividuals undergo less than 4 months of treatment, which
contradicts the current recommendations regarding anti-
depressant drugs.
As to the use of ADs, a consumption prevalence rate of
7.4% was reported in a general population study performed
in Germany [7]. Also, in another study conducted in the
US [8], 21.5% of the elderly population showed significant
depressive symptoms, and ADs were used in 7.5% of cases.
Effectiveness and safety of antidepressant drugs
While ADs can be effective if well prescribed, almost
50% of prescriptions issued by primary care centres are
aimed to treat subjects without a clear psychiatric diag-
nosis [9]. In addition, the ability to tolerate frustration
seems to be progressively declining in the most deve-
loped societies, and drugs are frequently sought as a so-
lution to personal and social everyday problems [10].
Other than an appropriate prescription, other aspects
such as doses used, early medication discontinuation,
and lack of follow-up by the family doctor must be
considered.Nowadays, the efficacy of ADs is very well established.
However, even the most optimistic clinical trials yield effi-
cacy rates of 70% and 40% for antidepressant and placebo,
respectively [11]. While ADs have shown to be more ef-
fective than placebo in the treatment of major depression,
their efficacy in the minor forms of the disorder have not
been shown [12]. The systematic review performed by
Kirsch [13] claims that only in case of severe disorders is
there a difference between antidepressants and placebo.
Another recent review only found small differences be-
tween the effects of antidepressants and placebo [14]. It
has been argued that mild depression – which in the past
frequently went undetected by the primary care phys-
ician– show a similar course regardless of whether they
are or are not identified. In this sense, part of the extraor-
dinary increase in AD prescription can be attributed to
this group of patients, who previously failed to receive
treatment for an indication without sufficient evidence of
efficacy data available [15]. In fact, in PC up to one fourth
of patients with a prescription for ADs collect their pre-
scriptions only once and do not continue treatment.
In general, the efficacy of all first-line ADs is similar,
and therefore the antidepressant selection process is
determined by the incidence and severity of adverse
effects, interactions, dosing convenience, patient charac-
teristics (age and concomitant diseases) or their beliefs
about treatment [16] and cost. The differences between
the different ADs mainly depend on their pharmacokinetic
characteristics and side effects. A meta-analysis [17] of the
efficacy and tolerability of SSRIs vs tricyclic antidepressants
in the treatment of depression in the primary care setting
showed evidence of similar short-term efficacy, although
tolerability for SSRIs was better.
Treatment compliance
In view of the safety of current antidepressants, clinical
guidelines have become more and more conservative in
determining the maintenance period of ADs [18]. Thus, it
is recommended that treatment be maintained for at least
1 year before starting gradual withdrawal, or to continue
for at least 6 months after obtaining a response in depres-
sive disorders [19]. Treatment compliance, however, is
low. Non-compliance is associated to an important risk of
recurrence of depressive disorders and evolution to chron-
icity [20,21]. In addition, therapeutic non-compliance
has also been associated with increased morbimortality
as well as mid- and long-term costs [22]. Several studies
have shown high rates of treatment dropout, ranging
from 30-40% during the first months [23,24] up to 50-60%
during the maintenance period [21].
A study performed to assess adherence to antidepres-
sant treatment reported correct intakes of prescribed
doses after 1 month of therapy in 82% of cases. This per-
centage fell to 69% after 3 months [25]. For most ADs,
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ance. However, although is really difficult to know whether
a patient actually takes his/her pills as prescribed, this is a
key factor to achieve and maintain improvement. This is
well illustrated by the fact that depression has been in-
cluded by the WHO in a monograph on “adherence”
to treatment for chronic diseases such as hypertension,
asthma, diabetes or epilepsy [26]. Other reasons for treat-
ment dropout have also been established: 23% of cases due
to adverse effects, 10% fear of drug dependence or in-
appropriate treatment, 10% for considering subjectively
that treatment is ineffective, and 9% for reasons attri-
buted to healthcare providers, who erroneously tell the
patient to discontinue treatment. Several measures have
been suggested to increase treatment adherence, such as
using better tolerated drugs, simplest drug administra-
tion schedules, help from relatives, pill reminders, psy-
choeducation, etc.
Estimating treatment compliance is a particularly com-
plex task that can involve patient self-reports, drug ac-
countability records, computerized packaging systems,
or plasma level determinations. Some of the studies have
even compared the validity of the different methods of
measurement. George et al. [27] compared 4 evaluation
methods in depressed patients treated in primary care
and showed that an electronic medication event moni-
toring system (MEMS) for daily pill count was the most
reliable method, followed by simple patient self-reports,
while plasma level determination was cumbersome and
quite inconvenient. In short, no simple, convenient, fully
reliable gold standard system is available [28].
Also to be acknowledged are factors related to good or
bad compliance, such as dose frequency, medication type,
etc. Relating to dose frequency, studies like that by Myers
and Branthwaite [29] failed to point out differences be-
tween once vs three times daily dosages, but compliance
was clearly better when the patient him/herself decided
on his/her own dosage regimen. Also interesting is the
drug type, where it has been suggested that SSRIs are far
better than tricyclics [30,31], with a lower percentage of
adverse effects but a higher dropout rate for lack of effi-
cacy. Other meta-analyses discussing this subject have
suggested that compliance depends on the involvement of
patients and healthcare providers in follow-up tasks, ra-
ther than the drug type itself, [32]. There is, however, a
limited number of studies on factors related to treatment
non-compliance with these drugs.
Other variables associated with better compliance include
psychiatrist follow-up or consumption of other medications
(excluding psychoactive drugs) [33]. In contrast, factors that
contribute to non-compliance include adverse effects on
sex life, self-perception of medication as being ineffec-
tive, female sex, low educational level [34], psychiatric co-
morbidity [21,35] and poor social support or functionallimitations in the elderly [36]. The studies on AD compli-
ance predictors frequently focus on a very limited range of
clinical and sociodemographic characteristics and so incon-
sistent results are sometimes obtained.
Satisfaction with antidepressant treatment
Satisfaction with treatment is part of the satisfaction with
the healthcare received [37]. It can be defined as the
evaluation of the process of drug treatment intake and its
outcome [38]. Another definition based on psychosocial
theories emphasizes the importance of the patient’s atti-
tude toward the different dimensions involved in his/her
treatment, and compares patient expectations with actual
facts [39]. Satisfaction is measured by means of standard,
validated questionnaires completed by the patients who
receive treatment. Satisfaction with treatment is expressed
in by a variety of dimensions that depend on the type of
treatment [37]. Most frequent dimensions include: symp-
tom relief, drug tolerability profile (some treatments may
be perceived by the patient as “worse than the disease”),
convenience of administration, etc. Satisfaction with the
impact of treatment on the dimensions involved in health-
related quality of life (HRQOL), such as physical or
psychological functions, is also included. Finally, general
satisfaction with treatment, and well as whether the pa-
tient would recommend it to other patients with the same
health problem, must be evaluated.
Given that a chronic patient is to take medication for a
long period of time, measuring satisfaction with treatment
in case of chronic therapies of diseases such as depression
is particularly recommended. Satisfaction with treatment
may be related to treatment compliance. A more satisfied
patient takes his/her medication properly for the prescribed
length of time and thus contributes to the desired thera-
peutic effect. In addition, satisfaction with treatment must
relate to the patient’s preferences. Indeed, when given the
opportunity to try different treatments, the patient will
choose the most satisfying one.
Rationale for the study
The clinical effectiveness of any therapy is determined by
the evaluation of (usually objective) clinical parameters of
the studied health condition. Hence, treatment success is
mainly based on the improvement or disappearance of
symptoms as well as on an objective assessment of the
physical or mental status by different measuring methods.
Health Outcomes Research complements clinical indi-
cators with other measurements that are more relevant to
the patient, such as health status and health-related qual-
ity of life (HRQoL).
Studies relating satisfaction to other clinical or self-
perceived health indicators are still scarce. The frequently
close relationship between satisfaction with treatment,
treatment compliance and effectiveness has already been
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tion, preferences and clinical or self-perceived measures
may depend on the characteristics of both the disease and
its treatment. Aspects that are most relevant to an asymp-
tomatic patient with a chronic disease, such as hyperten-
sion, will differ from those that are most relevant to patient
with a chronic symptomatic disease such as depression.
Convenient drug regimens may be preferred in the former,
while other aspects such as achieving symptom control as
soon as possible may be more important in the latter.
Few questionnaires on satisfaction with treatment have
been developed so far. Over recent years, some have
been developed to address health conditions such as dia-
betes, acne, erectile dysfunction, rheumatoid arthritis,
arthrosis, pain or chronic diseases in general [40-44].
However, no questionnaires on patient satisfaction and
preferences relating to depression treatment are cur-
rently available, and this aspect does bear a considerable
impact on the patient’s daily activities and HRQoL.
Research on satisfaction with treatment is still in its
early days, and many issues remain to be known and
analyzed in this field. Chronic processes in which thera-
peutic changes are frequent, increased numbers of drug
products marketed for the same disorder, and broader
access to information by the patient, all make him/her
wish to participate more in the decisions about his/her
treatment and the healthcare provider give more consid-
eration to the patient’s opinion [37].
It is reasonable to assume that the prescription and use
of the most successful drug products according to patient
satisfaction and preferences should eventually lead to bet-
ter treatment compliance and hence better effectiveness
and more benefit.
Long-term follow-up studies are required to help
physicians opt for the more effective and better tolerated
treatment options. This information should preferably
be generated by the healthcare providers themselves.
Publications studying the evaluation of antidepressant
treatment duration in Spain are scarce, and more studies
in the primary care setting are needed to clarify possible
differences in response among different antidepressants
with different mechanisms of action. Consequently, the
conduction of studies evaluating the clinical effectiveness
of different antidepressant therapies, the adherence to
them and their safety under actual conditions of use,
should be prioritized.
Study objectives
1. To develop and validate a specific tool to assess
satisfaction with antidepressant drug therapy and
determine its convergent validity with respect to the
main measurements conceptually related to the
assessed construct: clinical effectiveness, treatment-related beliefs and expectations, treatment
compliance, and tolerability.
2. To establish both clinical and sociodemographic
predicting factors of greater satisfaction with
antidepressant drug therapy.
3. To assess adherence to antidepressant drug therapy
and hence treatment compliance (self-reported, using
a validated questionnaire, by drug accountability and
using an electronic monitoring system) in patients
who initiate antidepressant drug therapy.
4. To analyze factors determining non-compliance from
both a clinical (concurrent diseases, consumption of
other drug products, etc.) and sociodemographic
viewpoint.
5. To evaluate the effectiveness of antidepressant drugs
on the remission of depressive symptoms by using
previously standardized instruments to evaluate
symptom severity and treatment-induced changes
(Hamilton Depression Rating Scale and
Montgomery-Asberg Depression Rating Scale).
6. To evaluate drug-related safety by describing adverse
effects of the different antidepressant drugs.
Methods
Design
This is a longitudinal observational study where a cohort
of adult patients initiating treatment with antidepressants
will be assessed after 15 days, 1, 3, 6, 9 and 12 months.
Study sites and subjects
This is a multi-centre study involving 20 Primary Care
centres distributed among the eight healthcare areas of
Castilla-La Mancha. This autonomous community has a
population of 1,977,304 inhabitants, that is, 4.32% of the
Spanish population [45].
Study subjects will include patients aged 18 years and
older, undergoing therapy with newly prescribed anti-
depressants. The accessible population will include users
of the Family Care Medicine surgeries of the participat-
ing Health Centres.
Inclusion criteria: patients aged 18 years and older initi-
ating treatment with antidepressants prescribed by the
family care doctor (GP), or a psychiatrist, or another spe-
cialist, who give their consent to participate in the study
once properly informed about its objectives.
Exclusion criteria: subjects with poor intellectual per-
formance that proves insufficient for them to collaborate
in the study; drug dependence; severe organic, mobility-
hindering diseases; and use of any antidepressant within
3 months prior to the initiation of the study.
Sample size
In order to achieve a 95% confidence level, a precision
of ± 4%, and an expected overall rate of non-compliance
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first months and 50–60% during maintenance treatment),
a total of 600 patients initiating treatment with antidepres-
sant drugs for the study period will need to be included.
Considering a 15% rate of non-responders and losses to
follow-up, a final sample size of 706 participants is ob-
tained. These will be selected by consecutive sampling at
the surgeries of the participating health centres.
Study variables
– Participant characteristics: age, sex, level of
education, occupation-based social class, type of
coexistence, marital status, type of funding for drug
products provision (active or pensioner), existence
or non-existence of temporary disability in case of
active workers (throughout the observation period)
and reason for attending, as well as visits to general
medicine surgeries in the previous 3 months.
– Antidepressant drugs: antidepressant type (NO6A
Group under the Anatomical Therapeutic Chemical
Classification [ATC]), dosage regimen, main reason
for prescription, prescribing physician (family doctor,
psychiatrist or other specialist), adverse effects,
previous consumption of antidepressants, reasons
stated by the patient to explain why he/she does not
take regularly or abandons his/her medication.
– Health status: health problems (International
Classification of Primary Care - ICPC – 2 –
WONCA), consumption of other drug products
(ATC Classification), history of depressive disorders
in the patient’s medical records and possible
concomitant psychotherapeutic treatments.
– Adherence to medication: self-reported compliance
(Haynes-Sackett Test), validated questionnaire on
extent of compliance based on clinical interview
(Morisky-Green Test) [46], drug accountability
(percentage of treatment compliance: number of
presumably consumed pills/total number of pills
that should have been consumed x 100). In a sub
sample of 50 randomly selected patients, compliance
will be evaluated by means of the Medication Event
Monitoring System (MEMS) (AARDEX,
Switzerland).
– Evaluation of depressive symptoms: depressive
symptom severity by means of the Hamilton
Depression Rating Scale [47] (17-item version),
adapted to Spanish and validated by Ramos-Brieva
and Cordero in 1986 [48]; change in the intensity of
depressive symptoms as a result of pharmacological
intervention by means of the Montgomery-Asberg
Depression Rating Scale (MADRS) [49], adapted to
Spanish by Conde and Franch in 1984 and validated
by Martínez R et al. in 1991 [50].– Beliefs about treatment, evaluated by means of The
Beliefs about Medicines Questionnaire (BMQ),
validated in Spain by Beléndez Vázquez in 2007 [51],
and degree of expectations fulfillment (questions
have 5 response options).
Satisfaction scale development and validation
The scale will be developed as follows: firstly, a thorough
review of the medical literature will be conducted to
identify all clinical manifestations of depressive patients,
all aspects related to the antidepressant treatment and
the contents of other satisfaction scales developed for
other conditions. As a result of this review, a first ver-
sion of the satisfaction scale will be prepared. Question
selection will be done according to interpretability, liter-
acy level, item extent, validity, discriminative ability and
homogeneity.
Then, a meeting will be held with a group of experts
in the disease (psychiatrists and family doctors) to evalu-
ate whether clinical manifestations as well as aspects
that are key to the patient’s satisfaction with depression
treatment are properly reflected in the questions. Ques-
tion content will be analyzed in terms of understanding,
format and applicability. Subsequent to this review,
modifications on the initial scale may be introduced and
questions may be added, this leading to a second version
of the scale.
The second version of the scale will be administered
to 15 patients undergoing antidepressant therapy. These
interviews will be aimed at validating the scale content
from the patient’s viewpoint. After scale administration,
a survey will be conducted to ascertain the patient’s
opinion on the level of understanding and applicability
of each question. This is how the final version of the
scale will be obtained. The questions included in this
final version will refer to specific aspects of treatment,
such as effectiveness (symptom control, absence of dis-
comfort and convenience) and daily life aspects in which
patients find particular improvement. The final scale will
include Likert-type questions with 5 response options,
where subjects will be able to express to what extent
they agree with the different assertions stated in the
scale (from “fully agree” to “fully disagree”).
Then, the measurement properties of the satisfaction
scale will be evaluated by having all selected patients an-
swer the questions included in the scale. Validity will be
completed by further collection of beliefs on antidepressant
treatments (The Beliefs about Medicines Questionnaire) as
well as of patient expectations at the beginning and at each
follow-up visit. Clinical effectiveness will be assessed by the
scores obtained in the Hamilton Depression Rating Scale
and the Montgomery-Asberg Depression Rating Scale.
The satisfaction scale will be re-administered to a
reduced group of patients, one week after the 1st- and
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a re-test to study instrument stability.
Data collection and information management
Patients will be selected at primary care centres by the
family care doctors who participate in the study. Once
briefed on the purpose of the study and the reasons for
their inclusion, patients will be addressed to the nursing
station, where they will undergo a structured interview.
They will be appointed for visits at 15 days, 1, 3, 6, 9
and 12 months for re-evaluation.
Data will be collected on a pre-coded questionnaire
specifically designed for this study. The questionnaire
will be prepared according to the following steps: selec-
tion of required information and appropriate scales (in-
cluding the previously developed scale of satisfaction
with antidepressant treatment), selection of question
type for each variable, code and score definition, ques-
tion ordering, questionnaire format design and instruc-
tion manual preparation.
A pilot test will be performed in a few individuals to es-
tablish the clarity of all questions and instructions included
in the questionnaire, and the time needed to complete the
interview. A standardized interview process will be used by
all nursing stations for more reliability. To this end, previ-
ous training sessions will be scheduled to ensure the uni-
formity of data collected by the nursing staff.
In order to minimize missing data and errors, the
answers will be checked by the interviewer in the pres-
ence of the interviewee, and incomplete or ambiguous
questions will be corrected. Responses will then be entered
in a database and reviewed periodically for incomplete or
erroneous data.
The initial visit will be performed by nursing staff
following prescription by the physician, and the following
variables will be collected in the data collection question-
naire: social-demographic data, previous (if applicable)
and present antidepressant treatment, dosage regimen,
diseases and other concomitant treatments, evaluation of
depressive symptoms and initial beliefs and expectations
about treatment.
At the first visit, the 50 patients assigned to the MEMS
system for compliance evaluation will be given the de-
vice, and its operation will be explained to them. Anti-
depressant prescriptions will be issued to the patients as
applicable. Patients will purchase their medication at the
pharmacy and will bring it back to the nurse. At the
time the patient produces the medication, blisters will be
removed from the box and each tablet, packed in its ori-
ginal packaging, will be cut out and introduced in the
MEMS system.
On successive visits (at 15 days and 1, 3, 6, 9 and 12 -
months), also performed by the nursing staff, information
will be obtained on: treatment compliance, patient-reportedadverse effects, reasons stated by the patient explaining
why he/she does not take regularly or abandons his/her
medication, modifications in antidepressant treatment or
concomitant medication, onset of new health problems, de-
pressive symptom re-evaluation, treatment satisfaction,
beliefs about treatment, and fulfilment of expectations
raised by antidepressant treatment.
Statistical analysis
Patient socio-demographic and clinical characteristics will
be described by means of proportions, measures of central
tendency and dispersion measures, according to the na-
ture of the variables. Data will be summarized by means
of tables and graphs, as appropriate. The corresponding
95% confidence intervals will be constructed and the re-
sponse rate will be described, listing the available features
of individuals who decide not to participate in the study.
Prior to evaluating the validity of the satisfaction ques-
tionnaire, feasibility will be evaluated in terms of percent-
age of unanswered questions. The first aspect of validity
analysed will be the ceiling and floor effects of each item,
defined as the percentage of patients with maximum and
minimum responses, respectively. The item-total correl-
ation (homogeneity index) will be established by measur-
ing the correlation between the scores of each item and
global scores. The Cronbach’s alpha statistic will be used
to check internal consistency.
For proper construct validity, scale content will be
analyzed qualitatively and checked for consistency with
the theoretical concept of satisfaction with treatment.
Underlying and fundamental dimensions will be explored
by factor analysis with factor extraction, using principal
component analysis, Varimax orthogonal rotation and
Promax oblique rotation, in order to establish the different
nuances raised in the questionnaire.
For content validity evaluation, the questions contained
in the questionnaire will be checked for inclusion of infor-
mation on all the dimensions involved in satisfaction with
antidepressant treatment. To this end, questions will con-
template aspects referring to all clinical manifestations
reported by depressive patients and to all aspects related
with the antidepressant drugs. All questions will be
supervised by clinically experienced psychiatrists and fam-
ily doctors.
Because criterion validity cannot be evaluated due to
lack of a gold standard of satisfaction with antidepres-
sant treatment, only its relationship with other variables
likely to be related can be evaluated, namely, fulfilment
of expectations created before starting treatment, clinical
effectiveness (reduction of depressive symptoms), ab-
sence of adverse effects and good therapeutic compli-
ance. Patients with better response in terms of clinical
effectiveness, better tolerability and better fulfilment of
expectations raised by treatment are expected to be
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validity will be assessed according to measurements con-
ceptually related to the evaluated construct (Morisky-
Green questionnaire, BMQ questionnaire, and Hamilton
and Montgomery-Asberg Rating Scales, etc.).
Sensitivity to change will be evaluated by quantifying
global score differences between visits. Change will be
assessed by repeated measures ANOVA. Stability, or
test-retest reliability, will be assessed in a sub sample of
patients by means of the intra-class correlation coeffi-
cient (ICC) between baseline measurement and the
measurement performed one week after.
The relationship between continuous variables will be
analyzed with the Pearson correlation coefficient, and
the relationship between two categorical variables will be
analyzed with the chi-square test (after verification of
the test conditions; if conditions are not met, Fisher’s
exact test will be used). A t-test comparing the means in
independent groups will be used to study the relation-
ship between binary and quantitative variables. When
assumption of normality and equality of variance are not
met in the distribution of any variable, a non-parametric
test will be used (Mann–Whitney U test for independent
groups). ANOVA and Kruskal-Wallis H test will be used
to compare means in more than two independent groups;
the H test will be used in case of unmet conditions for
ANOVA application, and in case of ordered categorical
variables.
Multivariate analysis (logistic regression models) will
be used to check the association of dependent variables
(treatment compliance, depressive symptom reduction,
onset of adverse effects and satisfaction with treatment)
with their conditioning factors. Statistical adjustment
will be performed and the existence of confounding fac-
tors and interaction variables will be checked. The pur-
pose of these analyses is to estimate partial regression
coefficients expressing the relevance of the different in-
dependent variables in explaining dependent variables
variability. These analyses will be conducted by means of
the Logistic Regression procedure of the program IBM
SPSS Statistics 19.0.
Ethics approval
This project was approved by the Research Ethics
Committee of the University Hospital of Albacete on
24 July 2008.
Discussion
The aim of this study is to address antidepressant drug
prescription in the Primary Care setting by evaluating
treatment compliance, clinical effectiveness to reduce
depressive symptoms, safety, and treatment satisfaction.
This will be done by identifying the determinants and
predictors of a better result in any of these aspects bymeans of a longitudinal study which involves one-year
follow-up of each participant.
Antidepressant drugs are an extraordinarily important
therapeutic group in the pharmacy composition; eco-
nomic repercussions and social impact associated to
their use is clear. Despite their well-established efficacy
in clinical trials, treatment non-compliance is a major
obstacle to their effectiveness in clinical practice. Ir-
regular drug intake and antidepressant treatment dis-
continuation have been associated with a greater risk of
therapeutic failure and recurrent depressive episodes.
The proposed study brings about useful conclusions to
improve the results of these drugs. Indeed, the empir-
ical identification of predictors of poorer adherence to
medication would allow these predictors to be considered
together with the patient during treatment, hence facilitat-
ing good compliance.
Additionally, devising a scale specifically designed to
evaluate satisfaction with antidepressant treatment could
be of interest in healthcare outcomes research. Thus,
designing of a reliable and clinically useful instrument to
evaluate treatment satisfaction will be attempted. This
instrument will be subsequently validated in the target
population where it is to be administered.
When preparing a scale of antidepressant treatment sat-
isfaction, the use of closed questions may prove quite use-
less to obtain complex information; also, it may lead to
response induction and may fail to collect important data.
This modality, however, will allow response uniformity
leading to easer coding. Should study losses be substantial,
failing to be randomly distributed –with subjects studied
not being representative of all patients treated with anti-
depressant therapy– a measurement bias could be present
and the validity of the study would be compromised. On
the other hand, the characteristics of the setting where the
study will be conducted (socioeconomic status, lifestyle,
etc.) may prevent the results from being directly applicable
to other settings.
This being a study to be conducted simultaneously in
several healthcare centres, protocol deviations or misin-
terpretations could lead to error. This will be prevented
by study staff training and certification.
The study will adhere at all times to the following eth-
ical principles: consent and voluntary participation, guar-
antee of complete privacy of information provided by
the patient and restriction of all data provided by the
interviewed patient to the scope of the proposed re-
search only. Investigators will ensure that the study is
conducted in full compliance with the declaration of
Helsinki and according to current legislation (Royal Decree
223/2004) and to the New Code of Medical Ethics and
Deontology approved by the Spanish Royal College of
Physicians. The study will fully adhere to Good Clinical
Practice guidelines.
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